China's first human chemogenetic trial cuts refractory epilepsy seizures by 92.6%

Chinese researchers report a 92.6% seizure reduction in the first human trial of chemogenetic therapy for refractory epilepsy, a novel approach using engineered proteins activated by an inert drug. The result is a single-arm early-phase study, so efficacy and safety remain unconfirmed in larger controlled trials. If replicated, this could offer a non-surgical alternative for the one-third of epilepsy patients unresponsive to medication.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works